Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov/Dec;134(6):599-607.
doi: 10.1177/0033354919881438. Epub 2019 Oct 10.

Reducing Health Care Disparities in Sickle Cell Disease: A Review

Affiliations
Review

Reducing Health Care Disparities in Sickle Cell Disease: A Review

LaTasha Lee et al. Public Health Rep. 2019 Nov/Dec.

Abstract

Sickle cell disease (SCD) is an inherited blood disorder most common among African American and Hispanic American persons. The disease can cause substantial, long-term, and costly health problems, including infections, stroke, and kidney failure, many of which can reduce life expectancy. Disparities in receiving health care among African Americans and other racial/ethnic minority groups in the United States are well known and directly related to poor outcomes associated with SCD. As an orphan disease-one that affects <200 000 persons nationwide-SCD does not receive the research funding and pharmaceutical investment directed to other orphan diseases. For example, cystic fibrosis affects fewer than half the number of persons but receives 3.5 times the funding from the National Institutes of Health and 440 times the funding from national foundations. In this review, we discuss the health inequities affecting persons with SCD, describe programs intended to improve their care, and identify actions that could be taken to further reduce these inequities, improve care, control treatment costs, and ease the burden of disease.

Keywords: Medicaid; access to care; community health centers; health care disparities; sickle cell disease.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Medical writing and editorial support were provided by Arjun Menon, PhD, Healthcare Consultancy Group, which was funded by Global Blood Therapeutics, Inc, South San Francisco, California.

Figures

Figure 1.
Figure 1.
(A) Estimated number of persons with sickle cell disease, based on state-specific African American and Hispanic birth-cohort disease prevalence and 2008 US Census population, corrected for early mortality. Map previously published by Hassell and reprinted with permission from the American College of Preventive Medicine. (B) Number of sickle cell disease treatment centers per state, 2017. Data source: Centers for Disease Control and Prevention (CDC). Used with permission from CDC.
Figure 2.
Figure 2.
All-cause mortality rates for sickle cell disease identified through population-based surveillance (2004-2008), the African American population (2008), and all populations (2008), in California and Georgia. Source: Paulukonis et al.

References

    1. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(suppl 4):S512–S521. doi:10.1016/j.amepre.2009.12.022 - PubMed
    1. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561–1573. doi:10.1056/NEJMra1510865 - PubMed
    1. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-2009). Pediatr Blood Cancer. 2013;60(9):1482–1486. doi:10.1002/pbc.24557 - PubMed
    1. Lanzkron S, Carroll CP, Haywood C., Jr Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep. 2013;128(2):110–116. doi:10.1177/003335491312800206 - PMC - PubMed
    1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–1644. doi:10.1056/NEJM199406093302303 - PubMed

Publication types

MeSH terms